Self-pigmenting textiles grown from cellulose-producing bacteria with engineered tyrosinase expression – Nature.com

K. rhaeticus culture conditions and culturing approaches

Two culture media were used in this study to culture K. rhaeticus. HS-glucose media (2% glucose, 10gl1 yeast extract, 10gl1 peptone, 2.7gl1 Na2HPO4 and 1.3gl1 citric acid, pH 5.65.8) and coconut water media (coconut water (Vita Coco), 0.05% (vol/vol) acetic acid). Coconut water media was sterilized by filtration, except in situations where more than 1l was required. In those situations, media supplements were sterilized separately and combined with coconut water, which had been opened and decanted out with aseptic technique, in the culturing container.

When K. rhaeticus was cultured on solid media, HS-glucose media was always used and supplemented with 1.5% agar. K. rhaeticus liquid cultures fell into the following two separate approaches: shaking cultures and stationary cultures. In shaking cultures, the media in use was supplemented with 2% (vol/vol) cellulase (Sigma-Aldrich, C2730) to allow for turbid growth without clumping. In stationary culture, where the goal is pellicle formation, media would be supplemented with 1% (vol/vol) ethanol to enhance pellicle production. In both approaches, where antibiotics were required for plasmid maintenance, media was supplemented with 340gml1 chloramphenicol or 200gml1 spectinomycin.

To facilitate consistency when inoculating multiple pellicles, K. rhaeticus cells would be grown in shaking growth conditions until turbid, normalized in OD600 across samples, pelleted by centrifugation and washed in the subsequent media to remove cellulase. The washed cells were used as a preculture and added, at a ratio of 1:25, into the culturing container and left in stationary conditions at 30C to form pellicles. In the case of forming large pellicles consistently (>25cm2), a glycerol aliquot approach was used. The K. rhaeticus strain of interest would be grown, shaking at 30C in 100ml of HS-glucose media until it reached an OD600 of ~0.6 to 1. At this point, the cells would be pelleted by centrifugation, washed in HS-glucose media, before being pelleted again and resuspended in 10ml of HS-glucose media containing 25% glycerol. The resuspended cells would be separated into 1ml aliquots and stored at 80C until use. When used, an aliquot would be thawed and added to the media in the final culturing container.

DNA parts and plasmids used in this study are listed in the supplementary materials. E. coli Turbo (NEB) cells were used for plasmid construction. The tyr1 DNA sequence was ordered from Twist Bioscience, with compatible 3 and 5 overhangs for entry into the KTK via Golden Gate Cloning. Constitutive tyrosinase constructs were built using the KTK. The procedures and protocols for working with the KTK are described in ref. 26. Plasmids containing the various versions of the Opto-T7RNAP system were kindly sent to us by A. Baumschlager and M. Khammash from ETH Zrich. Due to the presence of multiple KTK-incompatible restriction sites in the T7-Opto coding sequences, Gibson cloning was used to build both the pOpto-T7RNAP*(563-F2)-target plasmid and the five pOpto-T7RNAP suicide plasmids for genomic integration. The primers for Gibson cloning are listed in the supplementary materials.

K. rhaeticus electrocompetent cells were prepared as in ref. 24. K. rhaeticus cells were transformed using electroporation and selected for HS-glucose agar plates containing either 340gml1 chloramphenicol or 500gml1 spectinomycin, depending on the plasmid selection marker in use. Note, here a higher concentration of spectinomycin is used during normal culturing. Genetic constructs that were integrated into the chromosome of K. rhaeticus were done so by homologous recombination using a pUC19 suicide plasmid, as described in ref. 26.

Melanated pellicles were produced using a two-step approach. First, a tyr1 expression strain would be inoculated into a sterile culture container. Typically, 24-well deep well plates (Axygen) were used to make small pellicles. Each well contained 5ml of growth media and was inoculated at a ratio of 1:25 with preculture. Growth media was enriched with 0.5gl1 l-tyrosine and 10M CuSO4 to promote the highest eumelanin production. Once the pellicles had reached the desired thickness, they were collected, placed in a bath of sterile dH2O and washed for 1min by gently shaking by hand. The washed pellicles are then passed into a bath of eumelanin development buffer. A large ratio of buffer to pellicle was used, that is, one pellicle in 25ml of buffer in a 50-ml falcon tube; this was to prevent the overwhelming of the buffer by remaining acid in the pellicle. The pellicle would be allowed to produce eumelanin at >30C in shaking conditions over 24h.

To produce the melanated pellicle used to make the wallet, a 200300 Eurobox container was sterilized and filled with 3l of coconut water media supplemented with 0.5gl1 l-tyrosine, 10M CuSO4 and 1% ethanol. The media was inoculated with a 1ml K. rhaeticus ctyr1 glycerol aliquot and covered in a paper towel before being placed into a stationary incubator set to 30C. After 10days of growth, the pellicle was collected, washed briefly in dH2O before being placed in a 300400mm Eurobox containing 2l of concentrated eumelanin development buffer (10 PBS). The development container was then placed into a shaking incubator set to 45C and allowed to produce eumelanin over 2days, at which point the cellulose had become completely black. The melanated cellulose was then washed again to remove excess eumelanin development buffer before being autoclaved. To make the material pliable after drying, the cellulose sheet was left in a 5% glycerol solution. This glycerol process may improve the strength of dried BC by maintaining some of the properties of wet BC, by preventing hornification55. The sample was then pressed to remove bulk water and air-dried for 24h. This process typically leads to around a 98% reduction in mass due to the removal of water.

To produce the melanated pellicle used to make the shoe, a custom-shaped vessel, containing an apparatus that held a network of tightly strung yarn, was sterilized and filled with 2l of coconut water media supplemented with 0.5gl1 l-tyrosine, 10M CuSO4, 340gml1 chloramphenicol and 1% ethanol. The media was inoculated with a ~500ml precultured K. rhaeticus ptyr1 pellicle. To accommodate the fed-batch procedure and unique vessel size necessary to incorporate the yarn apparatus, the culture was left to grow at room temperature in stationary conditions, until a thin pellicle had formed. At this point, fresh coconut water media supplemented with 0.5gl1 l-tyrosine, 10M CuSO4, 340gml1 chloramphenicol and 1% ethanol was added, to raise the pellicle to just below the level of the tensed yarn. After a longer growth period of 2weeks due to lower temperature, the media was drained and replaced with concentrated eumelanin development buffer (10 PBS). The full container was placed into a shaking incubator set to 30rpm, and developed at 30C for 1day, at which point the pellicle had become completely black. The vessel was then drained of eumelanin development buffer, replaced with 70% ethanol and left overnight to sterilize. The ethanol was replaced with a 5% glycerol solution before the melanated cellulose was removed from the apparatus and wrapped around a shoe-shaped mold (last) to air-dry at 45C for 24h. Once air-dried, the shoe upper and last were placed onto a sole and photographed.

The eumelanin production assay uses a 384-square-well microtiter plate as a reaction plate. An OT-2 liquid handling robot (Opentrons) was used to prepare these reaction plates for the assay. Development buffer was placed into a deep well plate, from which 40l was transferred to each well in the reaction plate using an eight-channel 300l OT-2 Gen2 pipette. The reaction plate was kept at 4C to slow eumelanin production during plate preparation using the OT-2 thermo-module. Cells and supernatant potentially containing tyrosinase were placed into a 96-well plate. Cells were mixed in one round of aspiration using an eight-channel 20l OT-2 Gen2 pipette before 10l of cells were transferred into each well of the 384-well plate. Once full, the reaction plate was centrifuged for 10s to draw liquid to the bottom of the wells before being sealed with a Breath-Easy sealing membrane. The reaction plate was placed into a plate reader and heated to 45C to accelerate eumelanin production and prevent potential cell growth from affecting optical density readings. To measure cell density in the reaction plate, an initial measurement at OD600 is taken, after which OD405 measurements are taken every 10min for 12h, while the plate is shaken at high speed.

K. rhaeticus ptyr1, K.rhaeticus tyr1, and wild-type K. rhaeticus starter cultures were grown in 3ml of HS-glucose media, with 2% cellulase, 0.5gl1 tyrosine, 10M CuSO4 and, if appropriate, 340gml1 chloramphenicol, in shaking conditions for 24h. The cultures were normalized for OD600 and inoculated into shaking flasks containing 25ml of the same prior media for 48h. At this point, the cells were pelleted by centrifugation and the supernatant was transferred to a separate container on ice. The supernatant was sterilized using a 0.2-m filter and the pH was adjusted to pH 7 by 1M NaOH titration. The cell pellets were resuspended in eumelanin development buffer and 10l of the resulting mixture was placed into a 384-well plate alongside pH-adjusted supernatant samples and pH-adjusted cell cultures. Once full, the reaction plate was centrifuged for 10s to draw liquid to the bottom of the wells before being sealed with a Breath-Easy sealing membrane. Assay plate was run using the same protocol as used in the Eumelanin production assay.

K. rhaeticus ptyr1 was inoculated into a 24-well deep well plate, with each well containing 5ml of HS-glucose media, with 0.5gl1 tyrosine, 10M CuSO4 and 340gml1 chloramphenicol. After incubating at 30C for 7 days, pellicles were collected. Eumelanin production was initiated by placing the collected pellicles into eumelanin development buffer. A set of pellicles were held back from eumelanin production and placed into an acetate buffer containing 0.5gl1 tyrosine and 10M CuSO4 at pH 3.6 to act as a negative control. Melanated and unmelanated pellicles were sterilized by placing them in 70% ethanol overnight. Pellicles were then washed in distilled water to remove leftover ethanol and salt. Pellicles were then dried flat using a heated press set to 120C and 1ton of pressure. This process on average leads to a 98% reduction in mass of the pellicle. To facilitate this drying and prevent the pellicles from sticking to the press, pellicles were sandwiched between three layers of filter paper. Wettability tests were conducted using a KRUSS EasyDrop with 1l of water. Each contact angle measurement was derived from the average contact angle from ten back-to-back water drop images taken within 10s of drop contact with the pellicle surface.

K. rhaeticus ptyr1 was inoculated into 15-cm square Petri dishes containing 50ml of HS-glucose media, with 0.5gl1 tyrosine, 10M CuSO4 and 340gml1 chloramphenicol. After incubating at 30C for 7 days, pellicles were collected and cut into half. One half was placed into an eumelanin development buffer to initiate eumelanin production and the other half into an acetate buffer containing 0.5gl1 tyrosine and 10M CuSO4 at pH 3.6 to prevent eumelanin production. After 24h of shaking at 30C, melanated and unmelanated pellicles were removed from their respective buffers and sterilized in a 70% ethanol solution overnight. Pellicles were then washed in distilled water to remove ethanol and salts left over from the eumelanin development processes. Pellicles were then dried flat using a heated press set to 120C and 1ton of pressure. This process on average leads to a 98% reduction in mass of the pellicle. The 35-mm-long dog-bone test specimens were cut out of the dried cellulose using a Zwick ZCP 020 manual cutting press. Pellicle specimen ends reinforced with a card using Everbuild Stick 2 superglue. Dots were marked on the surface of each specimen for the optical measurement of displacement. A silver pen was used to dot melanated cellulose to generate the necessary contrast for optical measurement of displacement. Tensile tests were conducted with a Deben Microtest Tensile Stage using a load cell of 200N and cross-head speed of 0.5mmmin1.

The unmelanated pellicle was prepared by placing it into an acidic acetate buffer at pH 3.6, which prevented eumelanin synthesis and incubated in identical conditions to the melanated pellicle in the eumelanin development buffer bath. Melanated and unmelanated pellicles were prepared for SEM through the following steps. Unsterilized pellicles were placed in a 20% ethanol solution and shaken gently for 1h before being removed and placed into a 40% ethanol solution and shaken gently. This process was repeated for 60%, 80% and 100% ethanol solutions to ensure the maximum replacement of water with ethanol from the cellulose matrix. Pellicles were then flash-frozen in liquid nitrogen and freeze-dried until completely dry. The fully dried pellicles were then fixed on aluminum studs, sputter coated with gold and imaged at 5kV with a Zeiss Auriga Gemini FEG FIB-SEM.

K. rhaeticus ptyr1 and K. rhaeticus ctyr1 were separately inoculated into 3ml of HS-glucose media containing 2% (vol/vol) cellulase and 340gml1 chloramphenicol and grown shaking at 30C until turbid. The turbid cultures were then pelleted by centrifugation, washed with 1ml PBS and split into two separate 1.5ml centrifuge tubes. The cells were then pelleted again. One pellet was resuspended with 500l eumelanin development buffer to initiate eumelanin production and the other pellet was resuspended with 500l PBS to keep the cells unmelantated. The cells were incubated over 24h at 30C by which point the tube containing the cells in eumelanin development buffer had turned black. To prepare the microscope slides, 1l of melanated and unmelanated cells were placed on separate 1% agarose pads and imaged on a Nikon Ti-EX1 invert microscope with a 40 objective lens. Cells were imaged in bright field with no phase contrast to accurately represent the shade of the cells.

K. rhaeticus WT, K. rhaeticus ptyr1 and K. rhaeticus ctyr1 were inoculated into two-well deep well plates containing 50ml of HS-glucose media, with 0.5gl1 tyrosine, 10M CuSO4 and 340gml1 chloramphenicol. After 10days of incubation at 30C, pellicles were collected and placed into eumelanin development buffer. After 24h, pellicles were sterilized through autoclaving. Pellicles were then placed in a 20C freezer for 24h to minimize compression during sectioning. The frozen pellicles were sectioned by hand using a Leica DB80LX blade and imaged using a macro lens (Leica) on an RS Pro lightbox.

K. rhaeticus ptyr1 and K. rhaeticus ctyr1 were inoculated into 12.516.5cm2 two-well glass container with 200ml of HS-glucose media with 0.5gl1 tyrosine, 10 CuSO4 and 340gml1 chloramphenicol. After incubation for 7days at 30C, pellicles were collected. Eumelanin production was initiated by placing the pellicles into eumelanin development buffer. After 24h of shaking at 30C, pellicles were removed from the buffer and sterilized in 70% ethanol solution overnight. Pellicles were then washed in distilled water to remove ethanol and leftover salts. To make the material pliable after drying, replicate pellicles were placed in 0% or 5% glycerol solution overnight. Pellicles were then dried flat using a heated press set to 120C and 1ton of pressure. To facilitate this drying and prevent the pellicles from sticking to the press, pellicles were sandwiched between three layers of filter paper. Water spotting tests were adapted from ISO 105-E07:2010 standard. Eumelanated pellicles were secured onto an RS Pro lightbox, and 50l of distilled water was spotted onto each sample in triplicate. Pellicles were imaged before, immediately after and 16h after water spotting and assessed for color change.

A custom projection rig was built to project light onto the growing pellicle (Extended Data Fig. 7b). This held an acetate transparency that contained various components that would test the quality of the patterning in the pellicle. The image transparency was designed in Adobe Illustrator and printed on an HP LaserJet 500 MFP M570. Four acetate transparencies were stacked atop each other to form the final transparency. This was then sealed between glass slides and secured to the upper laboratory loop clamp. The pellicle container was sterilized and filled with 500ml of HS-glucose media, containing 0.1% (wt/vol) arabinose, 1% (vol/vol) ethanol and 170gml1 chloramphenicol. The media was then inoculated with a 1-ml K. rhaeticus pOpto-T7RNAP*(563-F2)-mCherry glycerol aliquot, and a glass lid was placed on top of the container. This glass lid was warmed before placement to prevent condensation forming on it and distorting the projection. The LED lamp was then turned on, and the lens shuttered with a piece of black card. After 3days at ~30C, a thin pellicle had formed. The lens was uncovered and the image from the transparency focused on the pellicle. Once the pellicle had been exposed to the projected image for 3days, it was collected and scanned using a FLA-5000 fluorescence scanner (Fujifilm). Image analysis was conducted using the OpenCV Python library.

A custom rig using a commercial LED projector (ViewSonic M1) was built to project light onto the growing pellicle (Extended Data Fig. 7e). The rig was draped with blackout fabric to remove outside light. A time-lapse image was designed in Adobe Illustrator to test how long a given pellicle would need to be exposed to light before an identifiable change in pigmentation could be observed. In this image, blue is represented by an RGB value of (0, 0, 255), cyan by (0, 255, 255), white by (255, 255, 255) and black by (0, 0, 0) (Fig. 4h). The pellicle container was sterilized and filled with 1l of coconut water media, containing 1% (wt/vol) arabinose, 0.5gl1 l-tyrosine, 10M CuSO4, 1% (vol/vol) ethanol and 200gml1 spectinomycin. The media was then inoculated with a 1-ml K. rhaeticus Opto-T7RNAP(563-F1)-tyr1 glycerol aliquot and the culture container was covered with foil. While this version of the optogenetic rig did contain a heater, in practice, we found this was only effective at heating the growth area by 12C above room temperature. After 8days at near room temperature (~20C), a thin pellicle had formed. The foil was then removed, the projector focused on the surface of the pellicle and the 80-h video started. After 80h, the pellicle was collected and placed into a 300400mm Eurobox containing 2l of concentrated eumelanin development buffer and left to develop in stationary conditions at 30C until a discernible pattern could be identified. The pellicle was then washed in dH2O to remove eumelanin that had not accumulated within the pellicle. Densitometry scans of the pellicle were taken using an Amersham Typhoon scanner (GE) and set to the digi-blue digitalization setting.

K. rhaeticus Opto-T7RNAP strains carrying the pT7-mCherry plasmid and K. rhaeticus pOpto-T7RNAP*(563-F2)-mCherry were cultured, in darkness, shaking in 3ml of HS-glucose media with 2% cellulase, containing either spectinomycin at 200gml1 or chloramphenicol at 340gml1 depending on the plasmid. When all cultures had become turbid, the OD600 was measured and cultures were all either diluted or concentrated to an OD600 of 1, before being inoculated (a ratio of 1:10) into a 96-well deep well plate containing 270l HS-glucose media with 2% cellulase and either 0, 1, 10 or 100mgml1 of arabinose. Where appropriate, spectinomycin at 200gml1 and chloramphenicol at 340gml1 were added to the wells. After 18h of shaking growth at 30C in darkness, cells were split across two clear 96-well plates, diluted 1:2 into fresh media with a matching arabinose concentration. One plate was placed onto a shaker under a blue LED flood light and the other plate was wrapped in foil and placed on the same shaker. Both plates were sealed with a Breath-Easy sealing membrane. After 6h in the two lighting conditions at 30C and fast shaking, the cells were placed into a plate reader, and red fluorescence in each well was measured using ex of 590nm and em of 645nm as well as cell density at OD600.

The Opto-T7RNAP K. rhaeticus strains carrying the pT7-tyr1 plasmid and K. rhaeticus pOpto-T7RNAP(563-F1)-tyr were cultured in the same manner as the mCherry strainswith the exception that the HS-glucose was supplemented with 0.5gl1 tyrosine and 10M CuSO4. The approach to exposing the cells to blue light was also the same as the mCherry strains, except, after 6h of exposure time, the two plates were entered into the eumelanin production assay procedure. The two plates were placed onto the OT-2 deck and samples from both plates were mixed with eumelanin development buffer in a 384-well reaction plate. Each well in the two 96-well plates was sampled twice in the 384 reaction plate to give two technical replicates for each well. These two replicates were then averaged during analysis.

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Read the original here:
Self-pigmenting textiles grown from cellulose-producing bacteria with engineered tyrosinase expression - Nature.com

Biotechnology Market Size to Reach USD 5.68 Trillion by 2033 – BioSpace

According to the latest research by Nova One Advisor, the global biotechnology market size was valued at USD 1.54 Trillion in 2023 and is projected to reach USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% from 2024 to 2033

Request PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)@ https://www.novaoneadvisor.com/report/sample/6732

The market is driven by strong government support through initiatives aimed at the modernization of regulatory framework, improvements in approval processes & reimbursement policies, as well as standardization of clinical studies. The growing foothold ofpersonalized medicineand an increasing number of orphan drug formulations are opening new avenues for biotechnology applications and are driving the influx of emerging and innovative biotechnology companies, further boosting the market revenue.

The COVID-19 pandemic has positively impacted the biotechnology market by propelling a rise in opportunities and advancements for drug development and manufacturing of vaccines for the disease. For instance, in 2021, over 11 billion doses of COVID-19 vaccine were produced globally, resulting in vaccination of about half of the worlds population within a year. Furthermore, the success of mRNA vaccines and accelerated approval processes have led to a surge in vaccine-related revenues, as evident by a combined revenue generation of around USD 31.9 billion in 2021 from Moderna, Pfizer/BioNTech, and Johnson & Johnson vaccines.

Expanding demand for biotechnology tools for agricultural applications including micro-propagation, molecular breeding, tissue culturing, conventional plant breeding & development of genetically modified crops, among others, have boosted the market growth. Moreover, genetically modified crops and herbicide-tolerant & insect resistant seeds are witnessing an increasing popularity and are contributing to the market growth. Rise in adoption of tissue culture technology for production of novel rice variants and disease- & pest-free banana varieties in regions of South Asia and Africa, and use of the technology for cloning of disease-free and nutritious plant varieties have propelled the agricultural applications for biotechnology.

The market is also driven by the presence of strong clinical trial pipeline and funding opportunities available in tissue engineering and regeneration technologies. As per the Alliance for Regenerative Medicine, companies developing cell and gene therapies raised over USD 23.1 billion investments globally in 2021, an increase of about 16% over 2020s total of USD 19.9 billion. Clinical success of leading gene therapy players in 2021, such as promising results from an in vivo CRISPR treatment for transthyretin amyloidosis, developed by Intellia Therapeutics and Regeneron, are significantly affecting the market growth.

Rising demand for clinical solutions for the treatment of chronic diseases such as cancer, diabetes, age-related macular degeneration, and almost all forms of arthritis are anticipated to boost the market. Major firms are investigating and developing pipeline products for diabetes and neurological disorders, such as Parkinsons & Alzheimers diseases, various types of cancers and cardiovascular diseases. For instance, according to clinicaltrials.gov, as of January 2021, there were 126 agents in clinical trials for the treatment of Alzheimer's disease, with 28 treatments in phase III trials.

Life sciences and healthcare sectors are experiencing a widespread use of fermentation technology and have positively impacted the market growth. Several modifications and advancements in the conventional bioreactors, such as introduction of simplified bioreactors and vortex bioreactors have led to improvements in the fermentation technology and growth in its adoption. Furthermore, vortex bioreactors have also been improvised for wastewater processing, to offer an enhanced operational feasibility. These modifications and improvement in fermentation technology are expected to accelerate market growth in the near future.

CAR T andTCR T-cell therapiesare being explored as potential treatment options against chronic viral infections, such as HIV, hepatitis B, and SARS-CoV-2. For instance, scientists at Duke-NUS Medical School are evaluating the use of T-cell therapy in combating the COVID-19 infection. The scientists have demonstrated that TCR-redirected T cells exhibit a functional profile comparable to that of SARS-specific CD8 memory T cells obtained from patients who have recovered from the infection. Such investigations are anticipated to spur further research prospects in this domain and drive the market growth.

Biotechnological techniques includingstem celltechnology, DNA fingerprinting, and genetic engineering, among other, are gaining significant traction since past few years. Technological advancement in stem cell therapeutics, increasing demand forbiologics, and a growing focus on the development of personalized medicines have resulted in a growing market for stem cell technologies. DNA fingerprinting applications are on the rise in forensic science, and for investigation of family relationships in animal populations as well as measurement of the extent of inbreeding. Similarly, genetic engineering and cloning techniques are being increasingly used in animal breeding and for manufacturing of complex biological substances.

Key Takeaways:

Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/6732

TYPES OF BIOTECHNOLOGY

Like the stripes of the rainbow, the different biotechnology applications are grouped generally into seven colours orresearch and development areas.In this section, we highlight the most relevant of each of them.

To these typologies, four further sub-categories with corresponding colours have more recently been added:

Biotechnology Market Trends

Ask here for customization study@ https://www.novaoneadvisor.com/report/customization/6732

Biotechnology Market Size in the U.S. 2024 to 2033

The U.S. biotechnology market size was valued at USD 246.18 billion in 2023 and is anticipated to reach around USD 763.82 billion by 2033, poised to grow at a CAGR of 11.90% from 2024 to 2033.

North America accounted for the largest share of 41% in 2023. The regional market is witnessing growth due to several factors, such as the presence of key players, extensive R&D activities, and high healthcare expenditure. The region has a high penetration of genomics, proteomics, and cell biology-based platforms that is accelerating the adoption oflife sciences tools. Furthermore, rise in prevalence of chronic diseases and rising adoption of personalized medicine applications for the treatment of life-threatening disorders is expected to positively impact the market growth in the region.

Asia Pacific is expected to expand at the fastest growth rate from 2024 to 2033. The growth of the regional market can be attributed to increasing investments and improvement in healthcare infrastructure, favorable government initiatives, and expansion strategies from key market players. For instance, in February 2022, Moderna Inc. announced its plans for a geographic expansion of its commercial network in Asia through opening of four new subsidiaries in Malaysia, Singapore, Hong Kong, and Taiwan. In addition, biopharmaceutical collaborations, such as Kiniksa Pharmaceuticals and Huadong Medicines strategic collaboration for development and commercialization of Kiniksas ARCALYST and mavrilimumab in the Asia-Pacific region are expected to drive the market growth.

Segments Insights:

Technology Insights

DNA sequencingheld a significant market share of 17.53% in 2023 which can be attributed to declining sequencing costs and rising penetration of advanced DNA sequencing techniques. Government funding in genetic research has enabled a rise in applications of sequencing for better understanding of diseases. For instance, in May 2021, a USD 10.7 million NIH grant was awarded to the University of Pittsburgh Graduate School of Public Health and Washington University School of Medicine in St. Louis, for investigation of the genetic basis of Alzheimers disease.

Nanobiotechnology is expected to grow at a significant growth rate from 2024 to 2033 owing to an increase innanomedicineapprovals and the advent of advanced technology. For instance, applications of theranostics nanoparticles have gained impetus for enabling prompt diagnosis and customization of treatment options for multiple disorders at once. Factors such as low toxicity, smaller size, and chemical plasticity of nanoparticles have proved to be beneficial for overcoming the limitation associated with conventional routes of generic drug administration. Furthermore, tissue engineering and regeneration medicine held a significant share due to government and private investments in the field, along with high healthcare spending and presence of significant number of mature and emerging players in this space. These factors are expected to drive the segment growth over the forecast period.

Application Insights

The health application segment accounted for the largest share in 2023. Growing disease burden, increasing availability of agri-biotech & bio-services, and technological developments in bio-industrial sector are expected to drive the segment growth. In addition, the segment growth is also fueled by significant advancements in the fields ofArtificial Intelligence(AI),machine learning, andbig data, which are expected to increase penetration of bioinformatics applications, especially in industries such as food and beverages.

Moreover, collaborative efforts and partnerships aimed at development and commercialization of new therapeutic platforms and molecules are anticipated to drive the market growth. For instance, in January 2021, Novartis collaborated with Alnylam for exploring the application of the latters siRNA technology for development of targeted therapy for restoration of liver function. Similarly, in September 2021, AstraZeneca and VaxEquity collaborated for development and commercialization of self-amplifyingRNA therapeuticsplatform to explore novel therapeutic programs. Furthermore, growing demand for biosimilars and rising applications of precision medicine are expected to boost segment growth during the forecast period.

Regional Insights

North America accounted for the largest share of 41% in 2023. The regional market is witnessing growth due to several factors, such as the presence of key players, extensive R&D activities, and high healthcare expenditure. The region has a high penetration of genomics, proteomics, and cell biology-based platforms that is accelerating the adoption oflife sciences tools. Furthermore, rise in prevalence of chronic diseases and rising adoption of personalized medicine applications for the treatment of life threatening disorders is expected to positively impact the market growth in the region.

Asia Pacific is expected to expand at the fastest growth rate from 2024 to 2033. The growth of the regional market can be attributed to increasing investments and improvement in healthcare infrastructure, favorable government initiatives, and expansion strategies from key market players. For instance, in February 2022, Moderna Inc. announced its plans for a geographic expansion of its commercial network in Asia through opening of four new subsidiaries in Malaysia, Singapore, Hong Kong, and Taiwan. In addition, biopharmaceutical collaborations, such as Kiniksa Pharmaceuticals and Huadong Medicines strategic collaboration for development and commercialization of Kiniksas ARCALYST and mavrilimumab in the Asia-Pacific region are expected to drive the market growth.

Recent Developments

Some of the prominent players in the Biotechnology Market include:

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Biotechnology market.

By Technology

By Application

By Region

Immediate Delivery Available | Buy This Premium Research https://www.novaoneadvisor.com/report/checkout/6732

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com|

Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |

Europe: +44 2080772818

See the article here:
Biotechnology Market Size to Reach USD 5.68 Trillion by 2033 - BioSpace

Plastic-free vegan leather that dyes itself grown from bacteria – EurekAlert

image:

The bacteria grown and dyed wallet

Credit: Tom Ellis/Marcus Walker/Imperial College London

Researchers at Imperial College London have genetically engineered bacteria to grow animal- and plastic-free leather that dyes itself.

In recent years, scientists and companies have started using microbes to grow sustainable textiles or to make dyes for industry but this is the first time bacteria have been engineered to produce a material and its own pigment simultaneously.

Synthetic chemical dyeing is one of the most environmentally toxic processes in fashion, and black dyes especially those used in colouring leather are particularly harmful. The researchers at Imperial set out to use biology to solve this.

In tackling the problem, the researchers say their self-dyeing vegan, plastic-free leather, which has been fashioned into shoe and wallet prototypes, represents a step forward in the quest for more sustainable fashion.

Their new process, which has been published in the journal Nature Biotechnology, could also theoretically be adapted to have bacteria grow materials with various vibrant colours and patterns, and to make more sustainable alternatives to other textiles such as cotton and cashmere.

Lead author Professor Tom Ellis, from Imperial College Londons Department of Bioengineering, said: Inventing a new, faster way to produce sustainable, self-dyed leather alternatives is a major achievement for synthetic biology and sustainable fashion.

Bacterial cellulose is inherently vegan, and its growth requires a tiny fraction of the carbon emissions, water, land use and time of farming cows for leather.

"Unlike plastic-based leather alternatives, bacterial cellulose can also be made without petrochemicals, and will biodegrade safely and non-toxically in the environment.

Designer collaboration

The researchers created the self-dyeing leather alternative by modifying the genes of a bacteria species that produces sheets of microbial cellulose a strong, flexible and malleable material that is already commonly used in food, cosmetics and textiles. The genetic modifications 'instructed the same microbes that were growing the material to also produce the dark black pigment, eumelanin.

They worked with designers to grow the upper part of a shoe (without the sole) by growing a sheet of bacterial cellulose in a bespoke, shoe-shaped vessel. After 14 days of growth wherein the cellulose took on the correct shape, they subjected the shoe to two days of gentle shaking at 30C to activate the production of black pigment from the bacteria so that it dyed the material from the inside.

They also made a black wallet by growing two separate cellulose sheets, cutting them to size, and sewing them together.

As well as the prototypes, the researchers demonstrated that the bacteria can be engineered using genes from other microbes to produce colours in response to blue light. By projecting a pattern, or logo, onto the sheets using blue light, the bacteria respond by producing coloured proteins which then glow.

This allows them to project patterns and logos onto the bacterial cultures as the material grows, resulting in patterns and logos forming from within the material.

Co-author Dr Kenneth Walker, who conducted the work at Imperial College Londons Department of Bioengineering and now works in industry, said: Our technique works at large enough scales to create real-life products, as shown by our prototypes. From here, we can consider aesthetics as well as alternative shapes, patterns, textiles, and colours.

"The work also shows the impact that can happen when scientists and designers work together. As current and future users of new bacteria-grown textiles, designers have a key role in championing exciting new materials and giving expert feedback to improve form, function, and the switch to sustainable fashion.

Greener clothes

The research team are now experimenting with a variety of coloured pigments to use those that can also be produced by the material-growing microbes.

The researchers and collaborators have also just won 2 million in funding from Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI), to use engineering biology and bacterial cellulose to solve more of fashions problems, such as the use of toxic chromium in leathers production lines.

Professor Ellis said: Microbes are already directly addressing many of the problems of animal and plastic-based leather, and we plan to get them ready to expand into new colours, materials and maybe patterns too.

We look forward to working with the fashion industry to make the clothes we wear greener throughout the whole production line.

The authors worked closely with Modern Synthesis, a London-based biodesign and materials company, who specialise in innovative microbial cellulose products.

This work was funded by Engineering and Physical Sciences Research Council and BBSRC, both part of UKRI.

Nature Biotechnology

Self-pigmenting textiles grown from cellulose-producing bacteria with engineered tyrosinase expression

2-Apr-2024

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

More:
Plastic-free vegan leather that dyes itself grown from bacteria - EurekAlert

Head of ClinicalTrials.gov job with National Library of Medicine, National Center for Biotechnology Information … – The Chronicle of Higher…

The National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM), National Institutes of Health (NIH) performs research on computational biology and creates and maintains information systems and computational tools for the biological research community. The NCBI is seeking a Program Head to manage the ClinicalTrials.gov project, a critical, highly visible, informational NIH resource, by providing leadership and technical and scientific direction in support of the transparency and disclosure of clinical research studies and their results. ClinicalTrials.gov contains information about ongoing and completed clinical studies from sponsors in the U.S. and abroad. It consists of a study registry and results database. The registry allows prospective participants to find information about recruiting studies of interest, enables researchers to characterize the clinical research landscape, provides an official repository for publicly declaring study protocol details, and facilitates the tracking of study completion and results disclosure. The results database, which complements journal publication, allows researchers to find complete, structured summary results based on the prespecified protocol for studies in an area of interest, thereby mitigating publication bias and selective reporting. This position directs program activities to optimize the value of the resource to stakeholders, while ensuring it meets policy and legal requirements. As of December 2023, ClinicalTrials.gov has over 473,000 study records, and over 61,000 records with results. More than 100,000 visitors use the website daily to find and learn about clinical studies. The data submission system, PRS (Protocol Registration and Results database), has about 20,000 unique logins per month and over 250,000 users. The Program Head manages over 40 scientific, technical, and administrative staff, is active in conducting and publishing research, participates in numerous scientific and policy activities and collaborations, and serves in an external advisory capacity.

Position Requirements

Candidates may be U.S. citizen, must have either a Ph.D., M.D. or equivalent doctoral degree, and must have experience in clinical trials methodologies, drug development procedures and clinical trials registries. The successful candidate will have demonstrated the skill and ability to direct, organize, and coordinate complex research and development projects and will have exceptional technical competence. Candidates should also have excellent communication skills and a proven ability to successfully engage with others to create useful resources and to achieve shared objectives. Salary and benefits are competitive, commensurate with education and experience.

How to Apply

Visit http://www.USAJobs.gov and access the detailed vacancy announcement https://www.usajobs.gov/job/778732800 beginning April 27th, 2024.Applications must be submitted online by 11:59 p.m. on May 1st, 2024.

Email ncbijobs@ncbi.nlm.nih.gov with questions or for more information about the position. Email Doug Bruno (douglas.bruno@nih.gov) with questions regarding how to apply. Visit NLM Careers to learn more about NLM and how you can play a role in this exciting and dynamic research organization.

HHS, NIH, and NLM are equal opportunity employers. DHHSandNIHareEqualOpportunityEmployers

Originally posted here:
Head of ClinicalTrials.gov job with National Library of Medicine, National Center for Biotechnology Information ... - The Chronicle of Higher...

Forbion participates in US financing rounds – European Biotechnology News

Forbion, the European life sciences venture capital firm from The Netherlands, announced its participation in oversubscribed Series B financing in Capstan Therapeutics Inc. and Engrail Therapeutics. Both companies are located in San Diego, USA.

Forbion is throwing a few million into the ring in order to participate in oversubscribed financing rounds in the USA. Both Series B financings have obviously generated a great deal of interest and both have exceeded their own targets. And both companies are based in San Diego, California (USA). And both times Forbion joined as a new investor.

Engrail Therapeutics announced the close of an oversubscribed $157m Series B financing round on 19th of March. The round was co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn Inc., Ysios Capital, Longwood Fund, Eight Roads Ventures, and existing founding investor Pivotal Life Sciences. Since its inception in 2019, the Company has raised over $220m. Engrail is a precision neuroscience company focused on the development of transformational therapies in anxiety disorders, depression, posttraumatic stress disorder, and rare neurodegenerative diseases.

With strong financial backing from highly sophisticated and dedicated life science investors, we are well positioned to deliver multiple value-creating milestones. Notably, we look forward to completing our ongoing ENX-102 phase 2 study in generalized anxiety disorder and advancing the rest of our pipeline into clinical development, said Vikram Sudarsan, Ph.D., president and CEO of Engrail Therapeutics. Jasper Bos, Ph.D. (Forbion) joined the board of directors at Engrail.

Only one day later at the same place, with some of the same actors, Forbion announced its participation as a new investor in the closing of a $175m oversubscribed Series B financing in Capstan Therapeutics, Inc.

The Series B financing was led by RA Capital Management, with additional participation from new investors Johnson and Johnson Innovation, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments. Capstans brings together some high-ranking corporate ventures of major pharmaceutical companies in existing investors Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly, Leaps by Bayer, Novartis Venture Fund, OrbiMed Advisors, Pfizer Ventures, Polaris Partners, and Vida Ventures who also participated in the round. Capstan is a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP). The Company also announced the appointment of Forbion General Partner Nanna Luneborg, PhD, MBA, to its Board of Directors. Commenting on her appointment to the Capstan BoardNanna Luneborg said, We are delighted to join the outstanding team and investor syndicate at Capstan Therapeutics. Capstan is pioneering in vivo CAR-T therapy, eliminating the need for ex vivo cell modification, and with the potential to create a scalable, off-the-shelf product to the benefit of patients across multiple different diseases.

Capstan marks the tenth investment from Forbions Growth Opportunities II Fund which raised 600m in 2023. However, the almost simultaneous large investments in the USA are not yet sufficient evidence of a general trend at Forbion to orientate its activities more transatlantically. A portion of the total amount from previous funds was always reserved for the USA.

See the rest here:
Forbion participates in US financing rounds - European Biotechnology News

Regulatory Status Review | Animal and Plant Health Inspection Service – USDA APHIS

Under the revised regulations, developers have the option of requesting a permit and/or a regulatory status review of a plant developed using genetic engineering that has not been previously evaluated and determined to be nonregulated. This process replaces the petition process in the preexisting regulations. When a developer requests a regulatory status review, APHIS evaluates whether the plant requires oversight based on the characteristics of the plant itself rather than on the use of a plant pest in its development. If a plant developed using genetic engineering is found to be unlikely to pose a plant pest risk, APHIS will not require regulation under 7 CFR part 340. If APHIS is unable to reach such a finding, it will regulate the plant and it would be allowed to move only under permit. Once APHIS determines that a plant is not regulated, subsequent transformation events using the same plant-trait-mechanism of action combination would not be regulated.

RSR evaluates plant pest risk based on:

RSR will include one or two steps, depending upon the plant.

STEP 1(APHIS will complete Step 1 in 180 days)

Evaluate the characteristics of the plant developed using genetic engineering relative to an appropriate comparator plant to identify whether a plausible pathway to increased plant pest risk exists and the corresponding factors of concern.

NOTE: A developer can request both a permit and that APHIS complete the second step in the process.

STEP 2(APHIS will complete its entire evaluation within 15 months)

Evaluate the identified factors of concern involving the plant developed using genetic engineering to determine the likelihood and consequence of the plausible increased plant pest risk.

View post:
Regulatory Status Review | Animal and Plant Health Inspection Service - USDA APHIS

Gezeiten’s biotech skincare works in harmony with your circadian rhythm – Wallpaper*

Gezeiten is a new skincare brand that takes its name from the German word for the ebb and flow of the sea tides. It is a fitting name, not only because the German-born brand uses marine extracts and mineral-rich, sub-oceanic water concentrate to create its products. But also because they are tailored to work harmoniously with the bodys natural rhythms for optimal results.

(Image credit: Courtesy of Gezeiten)

The brand was founded by two families: husband and wife Michaela and Michael Hiltebrandt, who are both scientists and creative brother and sister duo Charles and Claire Zurheide Bals. Collectively, they were drawn together by a belief that the skincare market is oversaturated with products, few of which deliver the results they promise. So they joined forces in the hopes of hitting on the secret that other brands were missing. We are interested in exploring human origins and revisiting how our skin functions as an organism, says the team over email. And also where we are headed, as human kind. This is precisely what has really driven our scientific journey with Gezeiten.

(Image credit: Courtesy of Gezeiten)

The result is a range of five products: a day cream, a night cream, a protecting serum, a rejuvenating serum and a seven-day treatment set. Each is formulated with the brands patented Earth Marine CellTech Complex, which is designed to prevent skin ageing at a cellular level by replenishing the skin barrier, supporting the skins natural healing process, detoxifying and hydrating.

The brand worked with biotech and marine biology experts to ensure that the formulation works; but they also recognised that to create truly cutting-edge and effective skincare, they had to ensure the ingredients were delivered to the skin at the most opportune moments. To do that, they developed daytime and nighttime formulations with time release functions to support the skins specific needs during the daytime stress phase and the nighttime regeneration phase.

(Image credit: Courtesy of Gezeiten)

By incorporating chronobiology (the study of the bodys rhythms) into the formulations, Gezeiten ensures that the products work to fill in the gaps a demanding, urban life creates, particularly when it comes to our disrupted sleep cycles. A major problem of our modern lifestyle is a disturbed circadian rhythm, which leads to skin disorders such as hypersensitivity of the skin, inflammation, eczema, and ultimately premature skin ageing, say the Gezeiten team.

(Image credit: Courtesy of Gezeiten)

We are focusing on synchronising disrupted circadian rhythms to maintain overall skin health, they continue. Sleep is important, but so is the quality of sleep and the stress we are exposed to. Cortisol levels also harm the skin, as does our lifestyle. The world has changed so much over the thousands of years and the skin is still the same. It is the interplay of different components that determines the quality and health of the skin. We take them all into account in the development of our current and future products.

(Image credit: Courtesy of Gezeiten)

After a month of use, the skincare starts syncing with the skins natural 28-day regeneration cycle, with a noticeable reduction of fine lines, wrinkles, and hyperpigmentation, as well as an increase in moisture.

Receive our daily digest of inspiration, escapism and design stories from around the world direct to your inbox

Our approach has led us to look at skin from a 360-degree point of view, says Gezeiten. So observing how the body works, active ingredients, the latest technologies on the market, and taking sustainability into account at every step, we have created a skincare range, but also the blueprint of skincare for the new age.

gezeiten.com

Read the original post:
Gezeiten's biotech skincare works in harmony with your circadian rhythm - Wallpaper*

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? – TradingView

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the First Trust NYSE Arca Biotechnology ETF FBT, a passively managed exchange traded fund launched on 06/19/2006.

While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency.

Sector ETFs also provide investors access to a broad group of companies in particular sectors that offer low risk and diversified exposure. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 5, placing it in top 31%.

Index Details

The fund is sponsored by First Trust Advisors. It has amassed assets over $1.18 billion, making it one of the larger ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. FBT seeks to match the performance of the NYSE Arca Biotechnology Index before fees and expenses.

The NYSE Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.

Costs

Expense ratios are an important factor in the return of an ETF and in the long term, cheaper funds can significantly outperform their more expensive counterparts, other things remaining the same.

Annual operating expenses for this ETF are 0.56%, making it on par with most peer products in the space.

Sector Exposure and Top Holdings

Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.

This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.

Looking at individual holdings, Grifols, S.a. (adr) GRFS accounts for about 4% of total assets, followed by Ultragenyx Pharmaceutical Inc. RARE and Iqvia Holdings Inc. IQV.

The top 10 holdings account for about 36.19% of total assets under management.

Performance and Risk

The ETF has lost about -2.71% and is up about 0.50% so far this year and in the past one year (as of 04/01/2024), respectively. FBT has traded between $132.50 and $160.46 during this last 52-week period.

The ETF has a beta of 0.67 and standard deviation of 21.95% for the trailing three-year period, making it a high risk choice in the space. With about 31 holdings, it has more concentrated exposure than peers.

Alternatives

First Trust NYSE Arca Biotechnology ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, FBT is a good option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.

SPDR S&P Biotech ETF XBI tracks S&P Biotechnology Select Industry Index and the iShares Biotechnology ETF IBB tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $7.45 billion in assets, iShares Biotechnology ETF has $7.64 billion. XBI has an expense ratio of 0.35% and IBB charges 0.45%.

Bottom Line

To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.

Zacks Investment Research

Read more from the original source:
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - TradingView

Yantai Zhenghai Biotechnology Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag – Simply Wall St

Key Financial Results

All figures shown in the chart above are for the trailing 12 month (TTM) period

Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) exceeded analyst estimates by 1.4%.

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are up 2.6% from a week ago.

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Yantai Zhenghai Biotechnology, and understanding this should be part of your investment process.

Find out whether Yantai Zhenghai Biotechnology is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Read more from the original source:
Yantai Zhenghai Biotechnology Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St

Pharmaceuticals and Biotechnology Manufacturing and Supply Agreements Trends Report 2024 with Directory of … – PR Newswire

DUBLIN, April 1, 2024 /PRNewswire/ -- The"Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2019-2024" report has been added to ResearchAndMarkets.com's offering.

Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter manufacturing and supply deals. Fully revised and updated, the report provides details of manufacturing and supply deals from 2019 to 2024.

The report provides access to manufacturing and supply deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of manufacturing and supply deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual manufacturing and supply contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of manufacturing and supply dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in manufacturing and supply as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of manufacturing and supply deals.

Chapter 4 provides a review of the leading manufacturing and supply deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active manufacturing and supply dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of manufacturing and supply deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the manufacturing and supply deal.

The deal directory includes a comprehensive listing of all manufacturing and supply deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

Key Benefits

Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology includes:

Analyzing contract agreements allows due diligence of:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in manufacturing and supply dealmaking 2.1. Introduction 2.2. Definition of manufacturing and supply deal 2.3. Trends in manufacturing and supply deals since 2019 2.3.1. Manufacturing and supply dealmaking by year, 2019-2024 2.3.2. manufacturing and supply dealmaking by phase of development, 2019-2024 2.3.3. Manufacturing and supply dealmaking by industry sector, 2019-2024 2.3.4. Manufacturing and supply dealmaking by therapy area, 2019-2024 2.3.5. Manufacturing and supply dealmaking by technology type, 2019-2024 2.3.6. Manufacturing and supply dealmaking by most active company, 2019-2024 2.4. Reasons for entering into manufacturing and supply partnering deals 2.5. The future of manufacturing and supply deals

Chapter 3 - Overview of manufacturing and supply deal structure 3.1. Introduction 3.2. manufacturing and supply agreement structure

Chapter 4 - Leading manufacturing and supply deals 4.1. Introduction 4.2. Top manufacturing and supply deals by value

Chapter 5 - Top 25 most active manufacturing and supply dealmakers 5.1. Introduction 5.2. Top 25 most active manufacturing and supply dealmakers

Chapter 6 - manufacturing and supply deals including contracts directory 6.1. Introduction 6.2. manufacturing and supply deals with contracts 2019-2024

Deal directory Deal directory - manufacturing and supply dealmaking by companies A-Z Deal directory - manufacturing and supply dealmaking by therapy area Deal directory - manufacturing and supply dealmaking by technology type

For more information about this report visit https://www.researchandmarkets.com/r/2zj9s3

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

See original here:
Pharmaceuticals and Biotechnology Manufacturing and Supply Agreements Trends Report 2024 with Directory of ... - PR Newswire

David Sinclair on Solutions Within Decades – Lifespan.io News

In this new interview, David Sinclair, Harvard professor and the author of Lifespan, explains his theory of aging, shares parts of his health routine, and reveals which directions in todays aging research excite him.

In the longevity field, when it comes to name recognition, theres David Sinclair and all the rest. Like in many other areas, this gap in popularity doesnt necessarily reflect the actual professional hierarchy. Dr. Sinclair, a Harvard professor, is undoubtedly a very prominent aging researcher, but he would probably agree (although we didnt ask) that he has many equally worthy colleagues.

Some of Dr. Sinclairs popularity stems from his highly successful Lifespan: Why We Age and Why We Dont Have To, a great entry-level book that did a lot to introduce the science of aging and the ideology of life extension to the public consciousness. Now, a new book is in the works, and it differs from the first one, Dr. Sinclair told us, in that Lifespan is the textbook, Lifespan II is the guidebook. That probably means we can expect some expert wisdom on how every one of us can stay healthier and live longer. Dr. Sinclair maintains an interesting personal routine, which we also asked him about.

Today, Dr. Sinclair is one of the most visible longevity advocates, expertly broadcasting the message of life extension from top-tier platforms such as Joe Rogans and Peter Diamandis podcasts. He carefully chooses his appearances at conferences, where he receives rock star-like attention.

All this does not mean that Dr. Sinclair has completely morphed into a public figure. On the contrary, he and his team at Harvard continue to produce some of the most interesting results in the field, which we have covered extensively. He is one of the pioneers in practical applications for partial cellular reprogramming, having demonstrated that it can regenerate crushed optic nerves in mice and non-human primates.

Like many high-profile researchers, Dr. Sinclair has his pet theory of aging. The current ruling paradigm is the Hallmarks of Aging, the processes that include genomic instability and telomere attrition. Together, they are responsible for the phenotype of aging that we are all familiar with. Scientists know that many if not all these processes are interconnected, but is there an actual hierarchy?

Dr. Sinclairs answer to that is yes. According to his Information Theory of Aging, cells health and function depend heavily on epigenetic information, a set of instructions in the form of slight chemical alterations to DNA molecules that governs the expression of genes and other elements of our DNA, such as retrotransposons. This is what tells cells into which cell type they should differentiate and how they should perform this types duties.

With time, various stressors throw our epigenome into disarray. Imagine pages of a manual being accidentally torn out, having coffee spilt over them, and so on. Epigenetic alterations are indeed one of the Hallmarks of Aging, and their contribution to aging is widely acknowledged. However, Dr. Sinclair takes it one step further.

First, those changes, he says, are responsible for a very significant part of aging that is, they are high upstream and influence many or all other hallmarks. Second, he postulates that there is a copy of the manual that can be used to restore the epigenome to its youthful state. We can see hints to this in cellular reprogramming, where cells can be either thrown back to their pluripotent (undifferentiated) state and almost completely rejuvenated, or partially reprogrammed and partially rejuvenated.

If we can find that pristine backup copy of cellular epigenetic information and learn how to use it, the possibilities are endless. A recent study by Sinclair et al. presents findings in support of the theory. Its not conclusive evidence yet, but definitely hope-inspiring. For more on this and other topics, we turned to David himself, and he kindly agreed to answer a few questions.

According to the Information Theory of Aging, epigenetic changes that disrupt gene expression patterns as we age are driven by cell stress and damage, such as DNA breaks. This process causes cells to lose their function and identity, to become exdifferentiated, and this may be a cause of many of the changes seen during aging, including some major age-related diseases.

Its not yet known how potent the effects of in vivo epigenetic reprogramming will be. We know it can improve the function of the eye to cure blindness in mice and monkeys and even improve the function of the brain, but whether it can fix the many problems that occur with age in the human body is not known.

The hypothesis predicts that there is chemical information in cells that encodes the youthful structure of the epigenome so that it can be reset, and gene expression can be restored to an earlier age. We know that it is possible to reset gene expression. We dont yet know for sure how and where this information is stored, but we are working hard to find these answers.

The hypothesis is that the backup copy stores the cells youthful chromatin structure that controls which RNAs and proteins are expressed. Resetting these structures allows the cell to regain its differentiated state and its youthful functions.

The hypothesis is that rejuvenation is important for germ cells and embryos to maintain youth. We speculate the putative backup copy is also important for the rebuilding of damaged organs and tissues. Many species can regrow entire body parts, from limbs to heads. With the exception of our livers, which can regrow after damage or surgery, we humans have largely lost the ability to regrow organs and limbs.

Species that live a long time are known to have a more stable epigenome than those that live shorter. We suspect this might be because they are better at preventing and repairing DNA damage, which we have shown can accelerate age-related changes.

Antagonistic pleiotropy is a process that is advantageous when organisms are young, but they cause problems later in life, when the force of natural selection is so weak they continue to exist in the germline. The processes that disrupt the epigenome seem to be useful in young organisms because they recruit chromatin factors to sites of broken DNA and increase DNA repair and stabilize chromosomes. We first saw this in yeast cells in Lenny Guarentes lab in the late 1990s, then later in mammals, in my own lab in the 2000s. The problem is that the recruitment doesnt reset fully, and chromatin regulators lose their place on the genome, causing exdifferentiation of cells. In 2007, we called this the Relocalization of Chromatin Hypothesis of Aging or RCM, and it was later incorporated into the Information Theory of Aging.

We have not seen any evidence for this claim after a decade of studying the system, the results of which are in the paper showing cells do not experience cytotoxicity. Our detailed response to the claim has been published in Cell.

We have a long way to go. Most people havent heard of aging research or the results that are being produced. Most doctors are also unaware of the advances in the field.

I think our biggest bottleneck is having access to old mice that we can study. One solution would be to have a source of them for all researchers.

Saying there is no known upper limit doesnt mean we can live for decades or centuries longer. I dont know of any technology that would allow Longevity Escape Velocity currently, but I also know saying something is impossible is a dangerous thing in this time of human history.

Im excited about senolytics, epigenetic reprogramming, and the use of AI in healthcare.

I have hopes we will be able to rejuvenate people in the next few decades. If all goes well, Life Biosciences will be testing vision restoration in humans in 2025.

Im not simply relying on anecdotes. Changing my lifestyle has resulted in changes to my blood biomarkers that are consistent to long-term health. Vegan diets are considered some of the healthiest of all, and this is backed by multiple human studies. Skipping meals so that my eating window is shorter, which is what I try to do, is backed by evidence indicating that it improves metabolic health and lowers inflammatory markers, among other benefits.

We know their safety profile. Metformin has been in tens of millions of people. Metformin and low-dose rapamycin appear to be relatively safe. Whether they are effective at slowing aging and safe in combination is not yet known.

After this interview was taken, David Sinclair has stepped down as President of the Academy for Health & Lifespan Research, as announced on X by another co-founder, Nir Barzilai.

To do this, we need your support. Your charitable contribution tranforms into rejuvenation research, news, shows, and more. Will you help?

Go here to see the original:
David Sinclair on Solutions Within Decades - Lifespan.io News

Nilam Resources flagged ‘buyer beware’ as shares pump over Bitcoin plans – Cointelegraph

Nilam Resources, a micro-cap company that touted plans this week to acquire $1.7 billion worth of Bitcoin (BTC), has been flagged as a public interest concern amid a meteoric 1,500% share price surge on Tuesday, March 26.

OTC Markets Group, the firm that runs OTC Pink, a platform for over-the-counter stock trading, currently labels Nilam Resources (NILA) as Caveat Emptor a designation it hands downto companies it deems worthy of buyer beware.

In a glossary page explaining the labels, OTC Markets explained that this public interest concern may stem from a spam campaign, questionable stock promotion, any known investigation of the company, regulatory suspensions, or any other disruptive corporate actions.

The OTC listing for NILA also shows it has been deemed a Shell Risk a label given to companies it thinks is likely a shell company based on its annual financial data and other income-related metrics.

On March 25, Nilam Resources, an investment holding company, announced it had entered into a Letter of Intent to acquire a company that plans to hold 24,800 Bitcoin.

Nilam Resources claimed the deal had been months in the making. It plans to issue a newly authorized preferred stock in exchange for the Bitcoin, which will be at a discounted rate relative to current market prices.

A day later, its share prices soared, reaching a new all-time high of 33 cents, up 1,700% from 1.8 cents last week. The companys current market cap currently stands at $280 million, according to OTCMarkets.

However, many crypto-natives arent convinced the firm will be able to follow through with its ambitious plan, with some suggesting the announcement is some kind of marketing stunt.

Bitcoin analyst and Adamant Researcheditor Tuur Demeester said he removed his initial tweet sharing Nilams announcement on X after a commenter pointed out that its indeed a stunt from a dying penny stock.

Quinten Francois, a crypto YouTuber and co-founder of Web3 company WhereAt Social also accused the filing of being a marketing stunt common among failing small-cap stocks.

Dylan LeClair, director of market intelligence at digital asset fund UTXO Management also shared doubts, noting the plan would only work if there were legitimate demand for the equity sale.

Likely flops and is for PR purposes, he added.

If Nilam is successful, the company will hold more Bitcoin than any other publicly listed company in the United States, except for MicroStrategy.

Related: MicroStrategy sells another $604M of notes to buy 9K Bitcoin

That would include beating Elon Musks Tesla and major Bitcoin miners such as Riot Blockchain, Hut 8 Corp, and Marathon Digital Holdings, according to data from BitcoinTreasuries.

Former Nilam Resources CEO Ron McIntyre has also reportedly cried foul over the announcement, telling Protos that the press release was issued without his review and that he didnt have detailed knowledge of the deal.

Asked why he resigned from his position, McIntyre reportedly replied:

There will be a FINRA investigation into Nilam Resources, he added.

Nila Resources describes itself as an investment holding company. In November last year, it announced it would be pivoting from health and wellness investments to frontier tech including medtech, fintech, and climate tech.

It followed up just a day later with an announcement it had acquired TechyTrade, a fintech technology provider.

Nilam Resources did not immediately respond to a request for comment.

Magazine: Asia Express Am I sorry? No 3AC founder. $6B BTC laundered for fast food worker: Asia Express

Go here to read the rest:

Nilam Resources flagged 'buyer beware' as shares pump over Bitcoin plans - Cointelegraph

BlackRock says bitcoin will be a good portfolio diversifier despite its recent rally with stocks – CNBC

Bitcoin is more like digital gold than a so-called "risk-on" asset, according to Robert Mitchnick, BlackRock's digital assets lead. For years, bitcoin's ability to behave in different ways at different times has stumped investors . They believed the idea that it might be a hedge against inflation only to see the cryptocurrency tumble with stocks in 2022 amid sky-high inflation and rate hikes and then rally again as signs of cooling began to show. BlackRock's Mitchnick, speaking at the Bitcoin Investor Day conference in New York City on Friday, acknowledged that bitcoin has at times acted like a high-risk tech stock, but said that isn't how it typically trades. "Historically bitcoin's long-term average correlation [to stocks] has been close to zero slightly positive, but close to zero," he said. "It's had periods where it's spiked, similar to gold .... Actually, if you put their correlation charts in a time series, they look remarkably similar ." BTC.CM= YTD mountain Bitcoin (BTC) YTD "One of the most confusing, unhelpful things that happened in the post-Covid era was you had people accept this idea that bitcoin was a risk-on asset," he added. "Bitcoin is a risky asset it is volatile, has a lot of uncertainty. But 'risk on' is a different thing it implies correlation to equities [and] fixed income." Digital gold has become the dominant bitcoin narrative again in the past year, as the cryptocurrency's correlation with the S & P 500 returned to 2021 lows and even briefly flipped negative this January. While the recent rally was spurred by the launch of U.S. bitcoin exchange-traded funds, some on Wall Street have suggested that it may have recently fused into the more macroeconomic-fueled gold rally . @GC.1 YTD mountain Gold in 2024 There is an exception to that view, however, according to Mitchnick. "Bitcoin has one fundamental macro variable where it is highly correlated with equities: It is massively short real interest rates" (or the difference between nominal rates and inflation indicator) "and it is long inflation expectations," he said. "Real interest rates drove every asset under the sun between 2020 and early 2023," he added. "They collapsed, therefore a lot of assets including bitcoin rocketed, and then they surged as the Fed started hiking and inflation expectations rolled over." Risk and portfolio construction That, understandably, adds confusion for newcomers to bitcoin investing, who are drawn to its digital gold-like qualities. With so many new institutional investors becoming exposed to bitcoin through the ETFs particularly BlackRock's iShares Bitcoin Trust , which has pulled in nearly $8 billion of investor cash the cryptocurrency's correlations are "probably the single most important debate right now in thinking about bitcoin," Mitchnick said. "[Clients] are trying to understand: In a small allocation, is this risk additive to the portfolio or actually is it potentially a diversifier or even a hedge?" he said. "It also is important for any investor to understand because it's the reason that bitcoin's generally not appropriate in a large concentration in a portfolio," Mitchnick added. "In a large concentration, its volatility becomes a huge driver of risk, but in a more modest concentration, the fact that generally it's been uncorrelated and it has different fundamental drivers potentially becomes a different source of return and even in some cases, a diversifier." BlackRock clients who are allocating to bitcoin, including financial advisors on behalf of their clients and large institutions, tend to limit their exposure to between 1% and 3%, he said.

Read more here:

BlackRock says bitcoin will be a good portfolio diversifier despite its recent rally with stocks - CNBC

BlackRock says bitcoin returns likely to come down now that it has been embraced by Wall Street – CNBC

If you're looking for your bitcoin to go to the moon, the window of opportunity may be slowly closing, according to BlackRock. That does not mean it has hit its ceiling or that there will not be rallies. However, as the cryptocurrency becomes more mature and institutionalized with the advent of exchange-traded funds, the days of its monster gains may become a thing of the past, according to Robert Mitchnick, BlackRock's head of digital assets. "Certainly, returns going forward will come down," he said at the Bitcoin Investor Day conference in New York City on Friday. "It's not going to return 124% a year over the next decade like it has the prior decade." He also pointed out that bitcoin's notorious volatility has fallen steadily over time and may continue to do so given the effect bitcoin ETFs have had on trading activity. This is a common view among investors. The idea is that by bringing more money and investors particularly institutional types with portfolio rebalancing strategies to the asset class, ETFs can enable more efficient price discovery as volumes increase. BTC.CM= .SPX,@GC.1 line 2014-03-26 Bitcoin is one of the top performing assets in the last 10 years This topic is part of the "education journey" BlackRock is on with its clients, whose demand for bitcoin exposure first spurred the firm's foray into this new asset class in 2021. That demand was "massive and clear" in 2023, when BlackRock filed to launch its iShares Bitcoin Trust. Mitchnick also said the firm is talking with clients about how bitcoin fits into their portfolio construction, and why the cryptocurrency will be a good diversifier despite its recent rally with stocks. "People need to be wary we'll have bull markets, we'll have bear markets too, even in this post-institutional world," he said. "And then what becomes interesting is, how do you think about the direction of volatility." With long-term volatility expected to continue decreasing, some investors wonder if bitcoin's four-year cycles roughly three years of an uptrend around the bitcoin halving followed by about a year of a downtrend could change as well. "I don't think we've seen the end of cycles in bitcoin," Mitchnick said. "By [bitcoin's] nature, there's reflexivity in it, and that's hard for a lot of traditional investors to wrap their heads around." Reflexivity refers to the self-reinforcing effect of market sentiment on the asset's performance. "[With] bitcoin, when the price goes up, the probabilities of success and adoption in some senses, as digital gold, are also changing," he said. "And when bad things happen and the price goes down, those probabilities are also changing." "So you create reflexivity, and that just reinforces the idea that you're going to have these cycles. I think they're still here to stay," he added. CNBC's Ganesh Rao contributed reporting.

The rest is here:

BlackRock says bitcoin returns likely to come down now that it has been embraced by Wall Street - CNBC

Bitcoin whale accumulation suggests pre-halving BTC rally will continue – Cointelegraph

Bitcoin (BTC) price rose above $71,000 for the first time since March 15 as capital flows into spot BTC exchange-traded funds (ETFs) turned positive.

Data from Cointelegraph Markets Pro and TradingView shows that BTC has risen more than 0.55% over the last 24 hours to hit a weekly high at $71,582 on March 26.

Several factors are fueling BTCs current price movement, including consistent spot Bitcoin ETF inflows, the upcoming Bitcoin halving and the overall positive investor sentiment among institutional investors.

Lets look at the factors behind Bitcoins rally on March 26.

Large Bitcoin investors have been adding to their holdings in anticipation of price increases in the future. Data from market intelligence firm Santiment shows that the percentage of wallets holding between 1,000 BTC and 10,000 BTC has increased from 23% on Jan. 1 to 25.17% on March 26.

As shown in the chart below, the percentage of those holding between 10,000 BTC and 100,000 BTC saw a sharp spike from 11.68% on March 2 to 12.42% on March 21 before slightly dropping to current levels of 11.98%

Bitcoin whale accumulation is supported by reducing BTC deposits on exchanges. According to Glassnode data, the number of deposit transactions to known exchange wallets started decreasing on March 5, when BTCs price climbed above $69,000.This drop continued on March 19 despite the price falling more than 9% on the day to close below $65,000, with deposits to exchanges declining from 109,420 transactions to 55,505 on March 25.

TheDecreasing transfer of BTC to exchanges suggests a lack of intent to sell, which is generally a bullish sign.

Instead, there has been an increase in the number of whales transferring Bitcoin from exchanges. On March 11, blockchain tracker and analytics firm Whale Alert flagged several transactions transferring large amounts of BTC from exchanges to self-custody wallets.

On March 25, one holder transferred 2,400 BTC, worth $169.5 million, from the Coinbase crypto exchange to an unknown new wallet.

Another whale withdrew 4,797 BTC, worth about $339 million, from Coinbase to an unknown wallet.

In a recent report, market data provider Glassnode said, The significant buying power of ETFs is set to overshadow the traditional supply squeeze effect expected from the upcoming Bitcoin halving set for April this year.

Glassnode analyst Marcin Miosierny wrote that the supply dynamics of Bitcoin are increasingly influenced by the actions of long-term holders (LTHs).

Miosierny advised traders to closely monitor the activity of LTHs, as their decisions to sell or hold can significantly impact market liquidity and sentiment.

The analyst added:

As the name implies, the Bitcoin supply halving is an event where the reward for mining new blocks on the Bitcoin blockchain is cut in half. After the next halving, the BTC rewards issued to miners per block will be reduced from 6.25 BTC to 3.125 BTC.

Crypto trader and analyst Rekt Capital shared a chart showing the 4 Phases of The Bitcoin Halving in a March 25 post on the X social network, saying the current cycle has been a story of Re-Accumulation Ranges and adding that there is a possibility for price going into the Halving is further consolidation at highs the Re-Accumulation phase.

As Bitcoins halving draws near, investors are rushing to place their best positions for the event.

Related: Bitcoin ETFs see $15M comeback as BTC price taps best close in 10 days

Bitcoin traders and analysts are now focusing on the next level for BTC after its rally back above $70,000. Data from IntoTheBlock shows that whales added more than 80,000 BTC when the price dropped to $64,000. According to the blockchain analytics firm, this buying appears to be the momentum behind Bitcoins move back to the $70K range.

The firms In/Out of the Money Around Price (IOMAP) model shows that BTC sits on relatively strong support around the $64,000 level compared with the resistance it faces in its recovery path.

What is clear is that traders are determined to hold the price above $70,000. According to independent analyst Daan Crypto Trades, investors should be ready for a crazy rise as $100,000 becomes the focus for the BTC price.

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision.

More:

Bitcoin whale accumulation suggests pre-halving BTC rally will continue - Cointelegraph

Over $6B worth of BTC moved by 5th-richest Bitcoin whale – Cointelegraph

The fifth-largest Bitcoin (BTC) holding address also dubbed 37X has moved over $6 billion worth of BTC to three new addresses for the first time since 2019.

The Bitcoin whale transferred nearly its entire balance of 94,500 Bitcoin, worth $6.05 billion, on March 23, leaving only 1.4 BTC in the initial address, according to a March 25 Xpost by Arkham Intelligence. It wrote:

The transfer occurred during a period of increased institutional interest in Bitcoin, driven by the upcoming Bitcoin halving, which will slash block issuance rewards in half when it occurs in late April.

Despite the Bitcoin price reaching an all-time high before the halving for the first time in history, the incoming supply issuance reduction is still not priced in to the full extent, co-founder of D8X decentralized exchange and former executive director at UBS told Cointelegraph.

Related: Is the Bitcoin halving the right time to invest in BTC?

The over $6 billion BTC transfer occurred two days before Bitcoin reclaimed the $70,000 psychological price level on March 25 for the first time in 10 days. As investors have resumed accumulating BTC off exchanges, BTC supply on Coinbase reached a nine-year low of 344,856 BTC on March 18.

Bitcoin rose 6.4% in the 24 hours leading up to 9:53 am in UTC to trade at $71,222, according to CoinMarketCap.

Bitcoins current rally is mainly driven by the anticipation of the halving and the increased institutional inflows from the ten spot Bitcoin exchange-traded funds (ETFs) in the United States, Christopher Cheung, partner at digital asset funds Ten Squared, told Cointelegraph in a research note:

Bitcoin ETFs have reached a combined total of $58.3 billion in on-chain holdings, which represents 4.17% of the current BTC supply, according to Dune.

Related: Who is Mr. 100? Mysterious Bitcoin whale becomes 14th-biggest BTC holder

More here:

Over $6B worth of BTC moved by 5th-richest Bitcoin whale - Cointelegraph

Hashdex’s new spot Bitcoin ETF to begin US trading on Wednesday – Cointelegraph

Asset manager Hashdex is officially joining the spot Bitcoin (BTC) exchange-traded fund (ETF) market in the United States after completing the conversion of its futures ETF to hold spot Bitcoin.

In a March 26 announcement, Hashdex said it has renamed and converted its Hashdex Bitcoin Futures ETF to the Hashdex Bitcoin ETF with the ticker DEFI.

DEFIs renaming corresponds to DEFIs completion of the conversion of its investment strategy to allow the Fund to provide spot Bitcoin holdings and its tracking of a new benchmark index effective March 27, 2024, it said.

The newly converted fund will invest at least 95% of its assets into spot Bitcoin, while up to 5% of the remaining assets will go into CME-traded Bitcoin futures contracts and cash and cash equivalents, according to the firm.

Since our founding in 2018, Hashdex has strongly believed that Bitcoin is a generational opportunity," said Hashdex co-founder and CEO Marcelo Sampaio.

Were excited to invite all investors whether it be those who already have full conviction in Bitcoin, those who are considering an allocation for the first time, or anyone in between to join us in our long-term journey of making digital assets accessible, added Samir Kerbage, Hashdexs chief investment officer.

Related:SEC pushes Hashdex, ARK 21Shares Ether ETFs as approval hope dwindles

Founded in 2018, Hashdex first joined the U.S. race for an approved spot in Bitcoin ETF in August 2023. Unlike others that depend on a Coinbase surveillance sharing agreement, Hashdexs fund acquires spot Bitcoin from physical exchanges within the CME market.

Hashdex is already several months lateto a competitive spot Bitcoin ETF market. According to data from Farside Investors, spot Bitcoin ETF cumulative inflow excluding Grayscales ETF is now at nearly $25.5 billion, though 80% of that figure is made up by BlackRock and Fidelitys ETFs.

A prospectus filed by Hashdex indicates its ETF charges a 0.90% a year management fee, which would sit on the higher end of fees charged by ETF issuers which average around 0.30%, but still under the 1.5% a year fee charged by the Grayscale Bitcoin Trust (GBTC).

Magazine:5 dangers to beware when apeing into Solana memecoins

Go here to see the original:

Hashdex's new spot Bitcoin ETF to begin US trading on Wednesday - Cointelegraph

Spot Bitcoin ETFs back in the black with $418M net inflows – Cointelegraph

Fresh capital is flowing back into US spot Bitcoin (BTC) exchange-traded funds (ETFs) following a five-day span of consecutive net outflows.

Led by strong inflows into Blackrocks and Fidelitys funds, the ten recently approved spot Bitcoin ETFs saw a combined net inflow of $418 million on March 26, according to Farside Investors data.

Fidelity's fund generated its largest daily inflow since March 13, notching $279.1 million on March 26 as the investment giant snapped up an additional 4,000 BTC. This marked the second consecutive day the fund has seen inflows exceeding $260 million.

Additionally, BlackRocks fund attracted inflows of $162.2 million. However, its daily inflows remain low compared to inflows earlier this month which averaged over $300 million per day.

Ark 21Shares Bitcoin ETF fund had its best day since March 12, notching $73.6 million in inflows while Invesco Galaxy, Franklin Templeton, and Valkyrie all saw more than $26 million worth of inflows across their respective funds.

Meanwhile, Grayscales Bitcoin Trust (GBTC) continued to bleed notching a daily outflow of $212 million, however, it was not enough to outweigh the net inflows of its competitors.

Since converting from a trust to an ETF on Jan. 11, Grayscale has shed a whopping 277,393 BTC worth roughly $19.5 billion at current prices.

Related: Hashdexs new spot Bitcoin ETF to begin US trading on Wednesday

In a March 26 post to X, Bloomberg senior ETF analyst Eric Balchunas noted the presence of Bitcoin ETFs in a chart of the largest 30 asset funds in their first 50 days of trading.

Four Bitcoin ETFs made the list of global funds with BlackRocks IBIT and Fidelitys FBTC in a league of their own, he exclaimed.

Balchunas noted that even the Bitwise Bitcoin ETF (BITB) currently the 18th largest Bitcoin ETF by assets under management was larger than the worlds largest SPDR Gold Shares (GLD) fund, he noted.

Crypto asset management firm Hashdex claimed its place as the eleventh spot Bitcoin ETF issuer in the United States on March 26 afterannouncingthe conversion of its futures fund to a spot product which now trades under the ticker DEFI.

Magazine: Bitcoin ETFs make Coinbase a honeypot for hackers and governments: Trezor CEO

More here:

Spot Bitcoin ETFs back in the black with $418M net inflows - Cointelegraph

Bitcoin ETF snapshot: Net outflow run hits five days for the first time – Blockworks

The 10 US spot bitcoin ETFs collectively saw net outflows each day last week an unprecedented streak for the so far successful segment.

The funds saw $888 million of investor money leave over the five-day span, according to BitMEX Research data. The largest outflow chunks came on March 19 and March 20, at $326 million and $262 million, respectively.

Those net outflows slowed later in the week, with $94 million coming on Thursday and $52 million flowing out on Friday.

BlackRocks iShares Bitcoin Trust (IBIT) had its all-time low flow total for a single day on Friday, tallying just $19 million, the BitMEX Research data shows.

Still, IBIT along with the Fidelity Wise Origin Bitcoin ETF have brought in net inflows during each of their first 50 days trading. Such a feat has never been accomplished by new ETFs, analysts note.

Read more: Bitcoin ETF catalyzing broader merge of TradFi, crypto: BlackRock exec

It was the first time the sector saw five straight days of net outflows. The ETFs had notched outflows on four straight days from Jan. 22 to Jan. 25.

The latest outflow streak came after a record week for the funds, during which they saw $2.5 billion of net inflows.

But bitcoins price dropped from nearly $68,000 on March 18 to below $61,000 on a slip of more than 10%. It fluctuated up and down later in the week, but remained well off its all-time high of more than $73,000 set on March 14.

BTCs price stood at $67,000 at about 7 a.m. ET Monday.

We believe the recent price correction led to hesitancy from investors, leading to much lower inflows into new ETF issuers in the US, CoinShares head of research James Butterfill wrote in a Monday report.

The new ETF bitcoin fund issuers exclude Grayscale Investments, which converted its Bitcoin Trust (GBTC) to an ETF on Jan. 11. GBTCs nine competitors have often been able to more than offset the higher-priced Grayscale funds persistent outflows, but not last week.

GBTC outflows amounted to about $2 billion, while the other nine funds brought in about $1.1 billion.

Bloomberg Intelligence analyst James Seyffart said in a Monday X post that outflows may have been driven in part by bankrupt lender Genesis offloading its shares of GBTC.

Expecting that to slow over the next week, he added.

Dont miss the next big story join ourfree daily newsletter.

Read the original here:

Bitcoin ETF snapshot: Net outflow run hits five days for the first time - Blockworks

Why Coinbase Analyst David Duong Expects to See ‘Continued Upside’ in Bitcoin – CoinDesk

We see that the probability of an E ETF being approved is actually super low. Now, I mean, previously about a year ago, it was somewhere around 80%. Now, it's gone down to around 17%. Um Maybe like it's been playing with 17 to 20%. But I would say for the most part, I haven't changed my view. I still think that the odds are in its favor. Uh You know, like for me, the only way it can actually be rejected is if easy, if is, if the SEC actually firmly came out and called this a security. It's Monday, March 25th, 2024 and this is market staley a show where we get into the minds of some of the smartest and most experienced investors, traders and analysts. I'm Jen Sani. Before we get into our discussion today, let's take a look at today's prices according to coindesk indices at 8 a.m. Eastern time. Bitcoin was up just over 2% at $66,818. Ether was up about 1.5% at $3435. And the coin desk 20 index was up 3% at 2590 points for more on the market's action. Let's bring in head of institutional research at Coinbase David Dang David. Welcome to the show. Hey Jaren. Thanks for having me. Of course, it's always a pleasure having you here, especially as we start to see some green in the markets this morning last week was was kind of depressing. If you're a markets watcher, talk to us about what happened and what you expect to happen from here. Overall, I think these Pullbacks within uptrend cycles are to be expected. And that's like for any asset class, right? I don't think cryptos uh particularly uh exceptional in that regard except to say that I do think that in previous cycles, we've seen Bitcoin give back like 30 to 50% of its gains. Um But comparatively, these moves have actually been pretty shallow. Uh I think the cryptos uh market's attention is just fixated on the flows over the fundamentals. So, you know, we saw that spot, Bitcoin ETF G at the first week of like real net outflows. Uh you know, in the, at least in the first few months, but definitely probably like since inception. And I think probably a lot of that had to do with actually uh probably some force selling pressure that I think is associated with genesis. But it's kind of hard to say at this point, but it just seems that the timing is very suspicious in my mind. I want to talk about Genesis in just a second, but you just mentioned previous cycles, talk to me about looking at this cycle and comparing it to previous cycles. Is there enough data? Especially since this Bitcoin ETF s have been introduced this cycle when you're comparing them, are you seeing information that is useful? I think it's really hard to generalize just because there are so few moments to actually draw from. And so when people kind of talk about major events happening, like the having and they kind of overlay the performance charts with those kind of like those kind of marks in them. Uh I myself am kind of just skeptical just because the performance if you actually go back just like, you know, and I do a very, you know, just small test of like six days before six days after really, you can't draw a lot of patterns from it. Like the first event was kind of a throwaway anyway, just because it was the first one that happened and no one knew what to expect. But even when you did, you have all these other macro factors that kind of interfered in that. And I don't think those things were a distraction like the pandemic, for example, there was real amounts of liquidity that kind of flowed through the market and that effectively changed things. And I think the same thing is going on right now. With the ETF S because they are real uh that's a demand sync for this asset class that didn't previously exist. And I think that's also changed the structure of the supply and dynamic uh supply and demand dynamics. OK. Let's get back to Genesis now before we forget and go into the having uh talk to us about the selling pressure. Is it coming from the bankruptcy estate? I know there's 35.9 million G BT shares, G BT C shares. Sorry, that are a part of that. Um What are you seeing there? So it's kind of tough to say that this is where the G BT C selling pressure is actually coming from. Uh you know, you can kind of say like, hey, we've had about $2 billion worth of outflows of the last week, Genesis had to sell worth about $2 billion worth of shares. Like are those two things the same? I mean, they had permission from the US banks of support since mid February to actually offload these shares. Um but what has changed is that there is a proposal out there that's been agreed with creditors to actually uh have 70 at least 77% of this, I believe uh actually be changed exchanged in kind. Now, you know, that's separate from the around 30 31 million shares that are actually associated with Gemini and you know that was a separate settlement and those all were gonna be paid uh with like in, in kind and probably within the next few weeks. But, you know, I, I think that it does kind of for me seem like this was the actual sell period. And if that's gonna be the case, then the market effect should actually be neutral because that means that they need to buy back the Bitcoin at some point. Uh They just don't have the cash yet. I think now that those trades are settling on the G BT C side. That's why we're starting to see kind of some recovery in the markets here. Tell us a little bit more about that 77% in kind. What does this mean for folks who are watching markets? Sure. So this was actually reported by the Wall Street Journal, I think on the 18th and effectively, they're saying that there is an outstanding creditor back proposal uh that returned those customer holdings in Bitcoin instead of cash. And the court approval actually said it could be paid either or so in, in effect, they could have just taken out the cash and actually paid out to clients. But you could see how that could potentially be to the detriment of the uh the creditors themselves. So I think that right now like what is fully clear to me is, is that inclusive of the other 31 million G BT C shares that they're discussing with Gemini, for example, but I don't believe that they are either way, it does suggest that it is the majority holdings that Genesis holds are going to be paid out in Bitcoin. And if they are, that means that they are selling GB DC and buying Bitcoin, so that means performance itself should be net neutral. Now, we mentioned the having just a few minutes ago and I want to get a little bit deeper into it. I know that you had a report that looked at past HS and you brought in the ETF data similarly to how we did at the beginning of this conversation. What are you expecting to happen? Um After the having, do you think it's priced in? Are we gonna, are we gonna stay in this price range for a little bit longer than some people maybe expect? I think that's the big question everyone's asking and the challenge I have is that people are looking at the having in a very like linear way, which is to say that they're basically saying like, hey, look, this is the man coming from the ETF S and I think that was why the flows actually disturbed so many people last week because they're saying like, have, have, have the flows, has demand for the uh for the ETF S actually stalled here. Is that a big concern? Um But you know, they comparing that just to one side of supply, which is the miners, they're saying like, well the miners actual new issuance of Bitcoin is going to be reduced by half. So if demand is increased so sharply because of the ETF S going into that limited supply, this is a huge boon for crypto. You are a huge boon for Bitcoin in particular. But crypto in general, I'd say that that's only one part of the story like supply obviously comes from multiple sources. And we've seen that if you even just look at the short term supply, which is really the active supply that's moved within the last three months, that has increased over the last quarter to like uh to the last few months in the beginning of 2024. So just the of course, uh Bitcoin issuance alone doesn't really speak for the 1.3 million Bitcoin that has made its way onto the market from those active sources. Now, that said we have seen that that has been absorbed pretty well, not just by the ETF S but probably by the community as a whole because you're seeing that even though the amount of Bitcoin hitting exchanges has doubled, uh the actual amount that's actually still left over is still something closer to like 80,000 Bitcoins. So really, it does show that like all of that uh Bitcoin that's been making its way on exchanges have been bought. But I'm just saying that it's not just the supply come from miners alone. We have to think about what the price point is where people will be willing to actually sell their shares and keep in mind that almost everyone now is pretty much in the money with their Bitcoin. So we're in real price, discovery territory in terms of not really knowing what the behavior is gonna be. Do you have any opinions on that, that you're willing to share? I think that we're gonna see continued upside. Uh, you know, like my overall thesis for the year was we're gonna start seeing a lot of inflows in January and February that played out pretty much as I expected. And that's why we wrote Constructive uh in early February, for example. But uh before we got into March, I was already saying that I was worried about particular headwinds coming in from the macro side, from the fact that I think that a lot of capital employment has already taken place. And that's not to say that more couldn't happen. And I think a big part of that has to do with the fact that for the most part, a lot of people missed this rally. I'm really talking about retail here, but we know that uh you know, retail were, they, they were under position, not just in crypto but pretty much in a lot of risk assets. They weren't, they didn't buy into equities last year, for example. And now there is a real catch up that we're seeing happen. And if we're thinking that there's another $6 trillion worth of capital that's still stuck in money market funds. For example, I mean, like once that's unlocked, I think, which is gonna happen later in the year when the fed really starts cutting rates. For example, I think that this will represent the, the next upside for an asset like Bitcoin and David. Just before I let you go here, I have ask you about this. Helene Braun is our host on Markets Daily on Wednesday and Thursday. And her reporting recently revealed that Black Rock says they're not seeing as much client demand for an ether ETF or for Ethereum. Um that along with some other new stories suggest that we may not see an Ether ETF in May. What's your perspective there? Yeah, this is tough and, you know, just last week we got the news that there was an inquiry uh to the Ethereum Foundation from an unidentified state authority, uh that they were, they, you know, they wanted information, but of course, that was super vague. No one has any clue about. I think people are speculating about who that quote unquote state authority could be. But I think that, you know, there are sources out there that I'm sure our listeners are familiar with or just jumping to conclusions that this is the sec and that these are the grounds on which an E ETF is going to be rejected. Honestly, I think that all of that is just, you know, just too speculative, right? Now to actually draw any real conclusions from, you know, we've seen that the probability of an E ETF being approved is actually super low. Now, I mean, previously about a year ago it was somewhere around 80%. Now, it's gone down to around 17%. Um, maybe like it's been playing with 17 to 20%. But I would say for the most part, I haven't changed my view. I still think that the odds are in its favor. Uh You know, like for me, the only way it can actually be rejected is if easy, if is if the SEC actually firmly came out and called this a security and that would go against what the CFTC has already said that this is in fact a commodity. Um And I don't necessarily think that they want to have an interagency fight about this. So I think that it's still gonna go through now, the timing of that, I think it's gonna be more challenging around the May 23rd period, which is when Van Eck is going to have uh their final deadline. But I still think that, you know, we're talking about greater than 50% odds here beyond that. I think that we are also seeing that some of the headlines have been in East favor. Like the fact that Blackrock wants to have this new uh Tokenization Fund, uh Biddle, I believe it's called, I think that that's being built on Ethereum, for example, So I think that that's going to be very supportive for e there's other sources that are gonna be helpful as well. So I wouldn't necessarily rely on just this. But if we're seeing that this uh uh the approval of the ETF has been priced out, E is doing fairly well, all things considered David. It's always a pleasure having you on Markets Daily. Thanks so much for joining the show. Thanks a lot, Jen. That was head of institutional research at Coinbase. David Dang. That's it for today's show.

Original post:

Why Coinbase Analyst David Duong Expects to See 'Continued Upside' in Bitcoin - CoinDesk